Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 17;6(5):100796.
doi: 10.1016/j.jtocrr.2025.100796. eCollection 2025 May.

Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?

Mariona Riudavets  1 , David Planchard  2
Affiliations
Editorial

Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?

Mariona Riudavets et al. JTO Clin Res Rep. .

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Planchard reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Celgene, Bristol-Myers Squibb, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Pfizer, Pierre-Fabre, Janssen, Roche, Abbvie, Takeda, Daiichi Sankyo, ArriVent, Mirati, Seagen, and GlaxoSmithKline; support for attending meetings and/or travel from AstraZeneca, Roche, Novartis, and Pfizer; participation on a Data Safety Monitoring Board or Advisory Board of AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Merck, Boehringer Ingelheim, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo, AbbVie, Janssen, Pierre-Fabre, Takeda, ArriVent, Mirati, and Seagen; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, and Daiichi Sankyo. Dr. Riudavets declares no conflict of interest.

Comment on

References

    1. Travis W.D., Brambilla E., Nicholson A.G., et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–1260. - PubMed
    1. Baudin E., Caplin M., Garcia-Carbonero R., et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32:439–451. - PubMed
    1. Rudin C.M., Reck M., Johnson M.L., et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16:66. - PMC - PubMed
    1. Cooper A.J., Rekhtman N., Baine M.K., Thomas M.C., Lynch A.C., Gentzler R.D. First report of response to tarlatamab in a patient with DLL3-positive pulmonary carcinoid: case report. JTO Clin Res Rep. 2024;5 - PMC - PubMed
    1. Yao J., Bergsland E., Aggarwal R., et al. DLL3 as an emerging target for the treatment of neuroendocrine neoplasms. Oncologist. 2022;27:940–951. - PMC - PubMed

LinkOut - more resources